Becton Dickinson's valuation is on the rise, following its strong quarterly results and revised profits. The company remains a favorable prospect due to its consistent dividend returns and stable company performance. The positive performance of its shares derived from the upgraded profit forecast and robust Q3 financial results, even though there were some mixed signals amid weak technicals. The recent move to STEP-UP U.S. manufacturing of critical medical devices and boosted innovation has led to raising its guidance for 2025. The company has recently submitted an application to the FDA for a new, At-Home HPV test that could potentially be a game changer. It continues to surprise Wall Street, surpassing earnings and revenue estimates, while securing a deal with Waters resulting in the expansion of biosciences and diagnostic solutions. However, despite its strong fundamentals, Becton Dickinson's forecast has been mixed, mainly due to market volatility.
Becton Dickinson and BDX News Analytics from Thu, 07 Nov 2024 08:00:00 GMT to Sat, 23 Aug 2025 13:27:38 GMT -
Rating 7
- Innovation 5
- Information 8
- Rumor -1
